May 13, 2020 | DNAe Technology Successfully Detects SARS-CoV-2 Sequences

DNAe, the next generation sequencing company developing novel diagnostics for use at the point-of-need, today announces positive results from internal tests using its LiDia-SEQ™ sequencing technology to identify SARS-CoV-2. The SARS-CoV-2 coronavirus is the cause of the COVID-19 pandemic currently causing extensive mortality, morbidity and disruption globally.

More

April 9, 2020 | FDA Grants Breakthrough Device Designation to DNAe’s Sequencing Diagnostic

DNAe, the next generation sequencing company developing novel diagnostics for use at the point-of-need, today announced that the US Food and Drug Administration (FDA) has granted it a “Breakthrough Device” designation for its pioneering platform and first assay.

More

April 9, 2020 | Internal Testing Underway of the LiDia-SEQ™ Technology for SARS-CoV-2

DNAe, the next generation sequencing company developing novel diagnostics for use at the point-of-need, today provides an update on its response to the COVID-19 pandemic and announces that internal testing is underway to evaluate use of the LiDia-SEQ™ sequencing technology for the current SARS-CoV-2 pandemic and to help in containing future outbreaks.

More

Dec 31, 2019 | 2019 Operational Update

DNAe, the next generation sequencing (NGS) company developing novel diagnostics for use at the point-of-need, provides an update on its significant research and development (R&D) and operational achievements in 2019.

More